INTRODUCTION

Lanadelumab (brand name Takhzyro) is a human monoclonal antibody (mAb) that is used to treat attacks of hereditary angioedema by targeting plasma kallikrein (pKal)and preventing angioedema in people with hereditary angioedema.

This plasmid is designed for expressing Lanadelumab in mammalian expression system such as HEK293 or Chinese hamster ovary (CHO) cell line.

PRODUCT INFORMATION

Item No.: PPBD-113
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options for promoter and selection marker, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Lanadelumab
Brand Name(s): Takhzyro
Classification: Monoclonal antibody (mAb)
Target: Kallikrein
Amino Acid Sequence: Identical to DB14597

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs. 2018 Feb/Mar;10(2):183-203. doi: 10.1080/19420862.2018.1415671. Epub 2018 Jan 16.

[2] Reichert JM. Antibodies to watch in 2017. MAbs. 2017 Feb/Mar;9(2):167-181. doi: 10.1080/19420862.2016.1269580. Epub 2016 Dec 14.

Contact Us